#BioNTech
-
BioNTech starts human trial to test malaria vaccine
-
Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1
-
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
-
U.S. FDA authorizes Moderna, Pfizer-BioNTech COVID-19 vaccines for kids down to 6 months of age
-
BioNTech posts tripled Q1 vaccine sales but still flags full-year decline
-
Israel signs deal with Novavax for COVID vaccine
-
Pfizer, BioNTech start clinical trial of Omicron-specific COVID-19 vaccine
-
Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine
-
AstraZeneca vaccine booster works against Omicron, Oxford lab study finds
-
Biontech, Pfizer to provide EU with extra 200 mln COVID doses
-
EU to supply 20 mln additional vaccine doses to fight Omicron variant
-
U.S. study suggests COVID-19 vaccines may be ineffective against Omicron without booster
-
Pfizer, BioNTech vaccine neutralises Omicron with three shots
-
Pfizer, BioNTech vaccine neutralises Omicron with three shots
-
BioNTech CEO confident of quickly adapting vaccine for Omicron
-
Pfizer/BioNTech, Moderna expect data on shot's protection against new COVID-19 variant soon
-
EU regulator gives go-ahead to first COVID shot for 5-11 year olds
-
Israel starts vaccinating young children as coronavirus cases rise
-
Pfizer expects COVID-19 vaccine sales of $29 bln in 2022
-
U.S. FDA advisers back Pfizer/BioNTech COVID-19 vaccine for children
-
Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children
-
Pfizer vaccine very effective against Delta variant in adolescents in Israel
-
Pfizer, BioNTech seek U.S. COVID-19 vaccine clearance for children 5-11
-
Portugal to give booster COVID-19 shot to older adults
